Tags Archive Navigation
icon
-
Media ReleaseNovartis investigational oral therapy iptacopan (LNP023) receives FDA Breakthrough Therapy Designation for PNH and Rare Pediatric Disease Designation for C3G
-
Media ReleaseNovartis receives complete response letter from U.S. FDA for inclisiran
-
Media ReleaseNovartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)
-
Media ReleaseNovartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
-
Media ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
-
Media ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
-
Media ReleaseNovartis renews WHO medicine donation pledge with aim of ending leprosy
-
Media ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
-
Media ReleaseNovartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
-
Media ReleaseNovartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
-
Media ReleaseNovartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemia
-
Media ReleaseNovartis Entresto® granted expanded indication in chronic heart failure by FDA
Pagination
- ‹ Previous page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- …
- 32
- › Next page